期刊文献+

利多卡因能相对延长心肌有效不应期吗? 被引量:1

Does lidocaine prolong effective refractory period of myocardium relatively?
下载PDF
导出
摘要 利多卡因抗心律失常的主要机制是抑制晚钠电流(I_(Na-L)),其缩短动作电位时程(APD)被认为是通过相对延长有效不应期(ERP),使更多的异位激动落在该期而失去作用,从而作为抗心律失常的一部分。然而,I_(Na-L)持续时间较长甚至其通道不失活,且心肌复极到-60 mV左右,内向整流K+通道开放,加速复极完成。外向阳离子流的增大削弱I_(Na-L)的影响致其作用并不明显。故利多卡因缩短APD更多的是缩短ERP,使ERP在APD中所占的比值下降并成为其致心律失常的基础,而不是相对延长ERP。其抗心律失常的主要作用在于抑制I_(Na-L)且恢复损伤细胞内外极性,提高心肌兴奋阈值,降低其兴奋性。 The anti-arrhythmic mechanism of lidocaine is mainly to inhibit the late Na+ current (INa-L), by whichmyocardial action potential duration (APD) is shortened, leading to the relative extension of effective refractory period(ERP). Therefore, more ectopic excitation will locate in ERP so as to lose their effect of initiating action potential.However, long opening time or un-inactivation of INa-L induced by lidocaine may cause rectifier K+ channels open whencardiomyocyte repolarizes to -60 mV, which eventually leads to accelerated repolarization. Thus, the enhanced outwardK+ current may reduce the effect of lidocaine-induced INa-L inhibition on APD. In summary, the final effect of lidocaineto shorten APD is to reduce ERP, which induces the reduction of the percentage of ERP in APD and eventually causesarrhythmia, but not extends ERP relatively. The mechanism of lidocaine in anti-arrhythmia is to inhibit INa-L and recoverthe polarization of damaged cells, which may increase the exciting threshold and decrease the excitation ability ofcardiomyocyte.
出处 《医学争鸣》 CAS 北大核心 2017年第1期49-52,共4页 Negative
关键词 利多卡因 心律失常 离子通道 动作电位时程 有效不应期 lidocaine arrhythmia ion channel action potential duration effective refractory period
  • 相关文献

参考文献3

二级参考文献73

  • 1Ball J, Carrington M J, MeMurray J J, el al. Atrial fibrillation: profile and burden of an ewdving epidemic in the 21st tenths,, lnt J Cardiol, 2013, 167: 1807-1824.
  • 2He XZ, Wang HY. Shen Y. el al. Cardiomyocyte progenitors in a canine pulmonary vein model of persistent atrial fibrillalion. J Cardiol, 2012, 60: 242-247.
  • 3Namekala I, Tsuneoka Y, Tanaka H. Eleclrophysiological and pharmacological properties of the pulmonary vein myocardinm. Biol Pharm Bull, 2013, 36: 2-7.
  • 4Harem S. Biology of the substrata of alrial fibrillation. Biol Aujourdhui, 2012, 206: 5-9.
  • 5Xu Y, Sharma D, Li G, et al, Atrial remodeling: New pathopiaysiological mechanism if atrial fihrillation. Med Hypolheses, 2013, 80: 53-56.
  • 6Sasaki N, Okumura Y. Watanabe I, et al. Pulmonary vein remnant as a trigger site for atrial fibrillalinn. Circ J, 2013, 77: 494-496.
  • 7Medi C, Kalman JM, Ling LH, et al. Atrial electrical and structural remodeling associated with longstanding pulmonary hypertension and right ventricular hypertrophy in humans. J Cardiovasc Electrophysiol, 2012, 23: 614-620.
  • 8Sossalla S. Kallmeyer B. Wagner S, et al. Altered Na+ eurrents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coil Cardiol. 2010, 55: 2330-2342.
  • 9Caballero R, de la Fuente MG, G6mez R, at al. In humans, chronic atrial fibrillation decreast, s lhe lransient outward currenI and uhrarapid component of tile delayed rectifier currenl differentially <>n each atria and increases the slow component of the delayed rectifier current in both. J Am Coil Cardiol, 2010, 55: 2346-2354.
  • 10Voigt N, Li N, Wang Q. et al. Enhanced sarcnplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation, 2012, 125: 2059-2070.

共引文献34

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部